Demo mode: simulated data, for showcase onlyDemo mode: simulated data, for showcase onlyDemo mode: simulated data, for showcase only
35%chance
Novo Nordisk has filed CagriSema (cagrilintide + semaglutide) for chronic weight management. Resolves YES if the FDA grants approval on or before Dec 31, 2026. Source: FDA / Novo Nordisk.
The recent news should move this significantly.
Interesting market. Watching closely before making a move.
Following this one closely. Lots of catalysts coming up.
The recent news should move this significantly.
I think people are overreacting. This won't happen.
Does anyone have a source for the resolution criteria?
Anyone have insights on the resolution criteria?
Adding to my position here. The odds are in our favor.
Great entry point at current prices. Loading up!
Looking at the data, this could go either way.
Anyone else think this is overvalued right now?
This needs more liquidity. Hard to get good fills.
Great analysis in this thread. Thanks everyone.